Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Journal of Clinical Psychopharmacology

Volumn 35, Issue 4, 2015, Pages 406-410

  Yu, Jing Jie ^a   Pei, Liu Bao ^b   Zhang, Yong ^a   Wen, Zi Yu ^a   Yang, Jian Li ^a  

^a Tianjin Anding Hospital   (China)

^b Shuangyashan Coal General Hospital   (China)

Author keywords

BDNF; cortisol; curcumin; depression; IL 1 ; TNF

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; DEMETHOXYCURCUMIN; HYDROCORTISONE; INTERLEUKIN 1BETA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CITALOPRAM;

ADULT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SALIVA; SOYBEAN; SUPPLEMENTATION; ANTAGONISTS AND INHIBITORS; BLOOD; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENT; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; HYDROCORTISONE; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84936952467     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000352     Document Type: Article

References (47)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Maheshwari RK, Singh AK, Gaddipati J, et al.Multiple biological activities of curcumin: a short review. Life Sci. 2006;78:2081-2087.
3. Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1973;25: 447-452.
4. Masuda T, Hidaka K, Shinohara A, et al. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem. 1999;47:71-77.
5. Wang R, Xu Y, Wu HL, et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 2008;578:43-50.
6. Xu Y, Ku BS, Yao HY, et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol. 2005;518:40-46.
7. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001;158:289-294.
8. Yehuda R,Giller EL, Southwick SM, et al. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry. 1991;30: 1031-1048.
9. Veen G, Giltay EJ, DeRijk RH, et al. Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism. 2009;58:821-827.
10. Xu Y, Ku B, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006;1122:56-64.
11. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol. 2007;7:18-21.
12. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
13. Huang Z, ZhongXM, LiZY, et al. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett. 2011;493:145-148.
14. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
15. Kiecolt-Glaser JK, Loving TJ, Stowell JR, et al. Hostilemarital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005;62:1377-1384.
16. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199-226.
17. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36:2452-2459.
18. Li Y, Zhang Y, Liu DB, et al. Curcumin attenuates diabetic neuropathic pain by downregulating TNF-alpha in a rat model. Int J Med Sci. 2013;10:377-381.
19. Rinwa P, Kumar A, Garg S. Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLoS One. 2013;8:e61052.
20. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12:332-347.
21. Sanmukhani J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28:579-585.
22. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86:321-322.
23. Ruiz de Azua S, Matute C, Stertz L, et al. Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis. BMC Psychiatry. 2013;13:27.
24. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270:24995-25000.
25. MaesM.Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:664-675.
26. Makhija K, Karunakaran S. The role of inflammatory cytokines on the aetiopathogenesis of depression. Aust N Z J Psychiatry. 2013;47:828-839.
27. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol. 2004;19:397-403.
28. Dowlati Y, Herrmann N, SwardfagerW, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
29. Huang WT, Niu KC, Chang CK, et al. Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol. 2008;593:105-111.
30. Belcaro G, CesaroneMR, DugallM, et al. Efficacy and safety ofMeriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15:337-344.
31. Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008;9:243-250.
32. Rajkowska G. Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res. 2000;126:397-412.
33. Cotter D, Mackay D, Landau S, et al. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545-553.
34. Campbell S,MacQueen G.An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry. 2006;19:25-33
35. Villanueva R. Neurobiology of major depressive disorder. Neural Plast. 2013;2013:873278.
36. Park SE, Lawson M, Dantzer R, et al. Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. J Neuroinflammation. 2011;8:179.
37. Smith MA, Makino S, Kvetnansky R, et al. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15: 1768-1777.
38. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
39. Pandey GN, Dwivedi Y, Rizavi HS, et al. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:645-651.
40. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
41. Adachi M, Barrot M, Autry AE, et al. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry. 2008;63:642-649.
42. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464-468.
43. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE States. Mol Psychiatry. 2002;7:254-275.
44. Harlow BL, Wise LA, Otto MW, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2003;60:29-36.
45. Li YC, Wang FM, Pan Y, et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:435-449.
46. Kumamaru E, Numakawa T, Adachi N, et al. Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. Mol Endocrinol. 2008;22:546-558.
47. Volak LP, Hanley MJ, Masse G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75:450-462.